Clinical Trials Logo

Filter by:
NCT ID: NCT05726097 Completed - Colon Cancer Clinical Trials

Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure

Start date: February 1, 2023
Phase: Phase 3
Study type: Interventional

The study aims to investigate the effect of the optimized bowel preparation and boost regimens on colon capsule endoscopy procedures, specifically on cleanliness and completion rate.

NCT ID: NCT05721014 Completed - Osteoporosis Clinical Trials

Effects of OsteoStrong vs. Individually Adapted and Combined Training on Bone Health

Start date: October 4, 2021
Phase: N/A
Study type: Interventional

The aim of this clinical trial is to investigate the effect of the OsteoStrong training method and the Individually Adapted and Combined Training on the bone health of older women with high fracture risk. Additionally, the aim is also to explore the participants' experiences of each training method. Participants will be randomised to either treatment arm A (OsteoStrong) or treatment arm B (Individually Adapted and Combined Training). Participants in both groups will train for nine months. Treatment arm A will train individually once a week and treatment arm B will train in a group twice a week. Both groups will have a training instructor who will supervise and give training instructions. Researchers will compare the groups to see the effects of the training methods on the participants' bone health among other outcome measures. The participants will be tested at baseline and post-intervention (9 months later).

NCT ID: NCT05696041 Completed - Clinical trials for Musculoskeletal Diseases

Wrist Stabilizing Exercise Versus Hand Orthotic Intervention for Persons With Hypermobility

Start date: August 1, 2014
Phase: N/A
Study type: Interventional

The goal of this study is to investigate if a Wrist Stabilizing Exercise Programme, WSE, compared to Conventional Intervention use of orthosis in daily activities, HO in persons with Hypermobility Spectrum Disorders, HSD or hypermobility Ehlers Danlos Syndrome, hEDS, in order to reduce pain and or paraesthesia in the hand. Participants are persons with HSD and hEDS with symptoms of persistent or intermittent pain and or paraesthesia in the hands for the past three years. The main question aims to answer - if the WSE has effect on occupational performance and health related quality of life - if the WSE has effect on handfunction and handstrength The intervention WSE aimed to improve wrist stabilization and increased grip strength according to a training program. Researchers will compare WSE and HO to see if there were changes between and within the intervention group, WSE and Convention group.

NCT ID: NCT05693441 Completed - Clinical trials for Age-related Cognitive Decline

Study on the Chronic and Acute Effects of Nordic Berry Beverage on Cognitive Function

SCANBerry
Start date: January 17, 2023
Phase: N/A
Study type: Interventional

The aim of the current study is to investigate whether acute and 12-weeks daily intake of Nordic berries can improve cognitive abilities of adults without cognitive disease, and whether the effect can be linked to changes in metabolic parameters.

NCT ID: NCT05693285 Completed - Clinical trials for Cardiovascular Diseases

Preterm Birth and Biomarkers for Cardiovascular Disease

BIO-PRETERM
Start date: November 14, 2022
Phase:
Study type: Observational

Preterm birth is associated with maternal increased risk of cardiovascular disease later in life. In an observational case- control study, investigators want to evaluate whether women with preterm birth have increased levels of biomarkers for cardiovascular disease, to reveal potential pathophysiological mechanisms in common.

NCT ID: NCT05688761 Completed - Drug Use Clinical Trials

Nordic Gastric and Esophageal Tumor Study

NordGETS
Start date: January 1, 2019
Phase:
Study type: Observational [Patient Registry]

This is a population-based case-control study in all 5 Nordic countries from 1994 onwards. All cases with an esophageal or gastric tumor will be compared with 10 times as many population controls, frequency-matched by age, sex, and calendar year, country. This design offers excellent statistical power, length and completeness of follow-up, quality of data on exposures, outcomes and confounders, and control for confounding. The project will include a specific study entitled "Long-term medication with proton pump inhibitors and risk of gastric cancer", which is summarized here: Research question: Medication with proton pump inhibitors (PPI) (e.g., omeprazole and esomeprazole) is one of the most common long-term therapies globally, prompted by its high anti-acidic efficacy and good short-term safety profile. Gastric cancer is the 3rd leading cause of cancer-related mortality globally, responsible for 770,000 deaths each year. There are clear biological mechanisms linking long-term PPI-use with an increased risk of gastric cancer. However, existing research has not been able to provide a definite answer to whether long-term PPI-use is associated with an increased risk of gastric cancer. The reasons are that the literature is hampered by too short follow-up time to assess cancer development, and also insufficient statistical power, lack of population-based design and confounding. With the availability of nationwide complete medication registries in the Nordic countries, the firsts two starting already in 1994 (Denmark and Finland), we can now, by adding registry data from all Nordic countries together, conduct the first study providing a robust and valid answer to this research question. Overarching aim This project aims to clarify if (and if so to what extent) long-term PPI-therapy influences the risk of developing gastric adenocarcinoma. For validation reasons, we will also examine how long-term use of histamine-2-receptor blockers (H2RB) influences the risk of developing gastric adenocarcinoma. These analyses will validate that the findings are specific for PPIs. H2RB are used for the same indications as PPIs, but with a different biological mechanism. Hypothesis We plan to test the hypothesis that long-term use of PPI (but not H2RB) increases the risk of gastric adenocarcinoma. Prerequisites This will be the first project with all prerequisites to provide conclusive answers to the hypotheses above, i.e.: - Long follow-up (up to 28 years) - Complete follow-up (by virtue of the nationwide complete Nordic registries) - Population-based design (which rules out biased selection of cases or controls) - Superior statistical power (all five Nordic countries participate with nationwide data) - High-quality data on exposures, outcomes and confounders (thanks to well-maintained and complete nationwide Nordic health data registries) - Control for confounding factors (available for all participants, both cases and controls)

NCT ID: NCT05687916 Completed - Narcolepsy Type 2 Clinical Trials

A Study of TAK-861 in Participants With Narcolepsy Type 2

Start date: January 9, 2023
Phase: Phase 2
Study type: Interventional

The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of Wakefulness Test (MWT). The study will enroll approximately 60 participants and they will be randomly assigned to 3 groups (20 per group) to take one of two different doses of TAK-861 or a placebo. All the participants will receive the treatment for 8 weeks. Participants will be asked to complete some questionnaires during the study. This trial will be conducted in North America, Europe, and Asia Pacific.

NCT ID: NCT05687903 Completed - Narcolepsy Type 1 Clinical Trials

A Study of TAK-861 in Participants With Narcolepsy Type 1

Start date: January 9, 2023
Phase: Phase 2
Study type: Interventional

The main aim of this study is to see how TAK-861 works on symptoms of narcolepsy, including excessive daytime sleepiness and cataplexy. Approximately 100 participants will take part in the study across North America, Europe and Asia Pacific. The treatment (TAK-861 or placebo) will be administered for 8 or 12 weeks. After this treatment period the participant will have the option to participate in a separate, long- term extension study during which all participants will be treated with TAK-861.

NCT ID: NCT05685953 Completed - Clinical trials for COVID-19 Respiratory Infection

A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine

OpenCorona1
Start date: February 8, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, placebo-controlled, double-blinded phase I study, designed to evaluate the safety including reactogenicity and immunogenicity of this investigational DNA vaccine delivered intramuscularly by in vivo EP in human adults. The vaccine doses will be given to healthy adults aged 18 to 60 years, who have been previously vaccinated against COVID-19 with 3 doses of either Comirnaty® or Spikevax®, or both in any combination ≥3 months ago.

NCT ID: NCT05674708 Completed - Inflammation Clinical Trials

Fat Quality and Postprandial Inflammation

PI:fat
Start date: February 7, 2023
Phase: N/A
Study type: Interventional

This aim of this randomized controlled postprandial study is to compare the effects of four different far sources (butter, coconut, corn oil and flax seed oil) on postprandial inflammation and metabolic response. The main questions it aims to answer are: 1. What is the impact of different dietary sources of saturated and polyunsaturated fatty acids on postprandial inflammation? 2. Is the impact of different dietary sources of saturated and polyunsaturated fatty acids on postprandial inflammation mediated by glucose or blood lipids? 3. Can postprandial inflammatory or metabolic response be predicted by individual factors at baseline? Participants will consume four meals, identical except for the fat source, in random order and sampled for blood and urine for up to 6 hours.